Stocks
Invest in Stocks
Invest in stocks, ETFs, IPOs with fast orders. Track returns on your stock holdings and view real-time P&L on your positions.
F&O
Mutual Funds
Invest in Mutual Funds
Invest in direct mutual funds at zero charges via lump sump investments or SIPs
ITI Pharma and Healthcare Fund Direct Growth
+21.65%
3Y annualised
-0.58% 1D
NAV: 10 Jun '26
₹18.17
Min. for SIP
₹500
Fund size (AUM)
₹229.56 Cr
Expense ratio
1.32%
Rating
2
Return calculator
Monthly investment
₹5,000
| Over the past | Total investment | Would've become | Historic returns | Returns |
|---|---|---|---|---|
| 3 months | ₹15,000 | ₹15,835 | +5.57% | |
| 6 months | ₹30,000 | ₹32,208 | +7.36% | |
| 1 year | ₹60,000 | ₹63,713 | +6.19% | |
| 3 years | ₹1,80,000 | ₹2,19,201 | +21.78% |
Holdings (40)
| Name | Sector | Instruments | Assets |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | Healthcare | Equity | 12.40% |
| Divi's Laboratories Ltd | Healthcare | Equity | 8.83% |
| Apollo Hospitals Enterprise Ltd | Healthcare | Equity | 6.25% |
| Max Healthcare Institute Ltd | Healthcare | Equity | 5.22% |
| Torrent Pharmaceuticals Ltd | Healthcare | Equity | 4.82% |
| Lupin Ltd | Healthcare | Equity | 4.44% |
| Aurobindo Pharma Ltd | Healthcare | Equity | 4.36% |
| Laurus Labs Ltd | Healthcare | Equity | 4.24% |
| Fortis Healthcare Ltd | Healthcare | Equity | 3.11% |
| Suven Pharmaceuticals Ltd | Healthcare | Equity | 3.08% |
| Neuland Laboratories Ltd | Healthcare | Equity | 3.05% |
| Alkem Laboratories Ltd | Healthcare | Equity | 2.93% |
| Glenmark Pharmaceuticals Ltd | Healthcare | Equity | 2.69% |
| Aster DM Healthcare Ltd | Healthcare | Equity | 2.24% |
| Mankind Pharma Ltd. | Healthcare | Equity | 1.91% |
| Sai Life Sciences Ltd. | Healthcare | Equity | 1.84% |
| Dr. Reddy's Laboratories Ltd | Healthcare | Equity | 1.82% |
| Abbott India Ltd | Healthcare | Equity | 1.79% |
| Net Receivables | Unspecified | Net Receivables | 1.75% |
| Park Medi World Ltd. | Healthcare | Equity | 1.67% |
| Cipla Ltd | Healthcare | Equity | 1.64% |
| Ipca Laboratories Ltd | Healthcare | Equity | 1.50% |
| Linde India Ltd | Materials | Equity | 1.37% |
| Sun Pharmaceutical Inds. Ltd Futures | Healthcare | Futures | 1.36% |
| Shaily Engineering Plastics Ltd | Materials | Equity | 1.29% |
| Jubilant Ingrevia Ltd | Materials | Equity | 1.28% |
| SBI Life Insurance Company Ltd | Financial | Equity | 1.26% |
| FDC Ltd | Healthcare | Equity | 1.21% |
| Piramal Pharma Ltd | Healthcare | Equity | 1.20% |
| Biocon Ltd | Healthcare | Equity | 1.19% |
| Healthcare Global Enterprises Ltd | Healthcare | Equity | 1.09% |
| Rainbow Childrens Medicare Ltd | Healthcare | Equity | 0.99% |
| Glaxosmithkline Pharmaceuticals Ltd | Healthcare | Equity | 0.94% |
| Standard Glass Lining Technology Ltd. | Industrials | Equity | 0.91% |
| Shilpa Medicare Ltd | Healthcare | Equity | 0.88% |
| Poly Medicure Ltd | Healthcare | Equity | 0.79% |
| Caplin Point Laboratories Ltd | Healthcare | Equity | 0.78% |
| Supriya Lifescience Ltd | Healthcare | Equity | 0.77% |
| Zydus Lifesciences Ltd | Healthcare | Equity | 0.65% |
| Syngene International Ltd | Healthcare | Equity | 0.45% |
See All
Minimum investments
Min. for 1st investment
₹5,000
Min. for 2nd investment
₹1,000
Min. for SIP
₹500
Returns and rankings
Annualised returns
Absolute returns
| Name | 6M | 1Y | 3Y | All |
|---|---|---|---|---|
| Fund returns | +6.2% | +4.3% | +21.6% | +13.9% |
| Category average (Equity Sectoral) | +0.2% | -2.1% | +22.1% | -- |
| Rank (Equity Sectoral) | -- | 18 | 9 | -- |
Exit load, stamp duty and tax
Exit load
Exit load of 0.50%, if redeemed within 3 months.
Stamp duty on investment: 0.005% (from July 1st, 2020)
from July 1st 2020
Tax implication
If you redeem within one year, returns are taxed at 20%. If you redeem after one year, returns exceeding Rs 1.25 lakh in a financial year are taxed at 12.5%.
Check past data
Fund management
RBRajesh BhatiaJun 2024 - PresentView details
RB
Rajesh Bhatia
Jun 2024 - Present
View details
ASAnimesh SinghMay 2026 - PresentView details
AS
Animesh Singh
May 2026 - Present
View details
NDNilay DalalMay 2026 - PresentView details
ND
Nilay Dalal
May 2026 - Present
View details
About ITI Pharma and Healthcare Fund Direct Growth
ITI Pharma and Healthcare Fund Direct Growth is a Equity Mutual Fund Scheme launched by ITI Mutual Fund. This scheme was made available to investors on 14 May 2018. Rajesh Bhatia is the Current Fund Manager of ITI Pharma and Healthcare Fund Direct Growth fund. The fund currently has an Asset Under Management(AUM) of ₹11,161 Cr and the Latest NAV as of 10 Jun 2026 is ₹18.17.
The ITI Pharma and Healthcare Fund Direct Growth is rated Very High risk. Minimum SIP Investment is set to ₹500. Minimum Lumpsum Investment is ₹5,000. Exit load of 0.50%, if redeemed within 3 months.
;
Investment Objective
The scheme seeks to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare.
Fund benchmarkNIFTY Healthcare Total Return Index.
Fund house
Rank (total assets)--
Total AUM₹11,161.50 Cr
Date of Incorporation14 May 2018
Launch Date14 May 2018
AddressITI Asset Mangement Limited,ITI House, Building no. 36,Dr. R. K. Shirodkar Marg, Parel, Mumbai 400012
Websitewww.karvymfs.com
AddressKarvy House, No. 46, 8-2-609/K, Avenue 4, Street No.1 Banjara Hills,